This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Company News for Mar 31, 2021
by Zacks Equity Research
Companies in The News Are: BNTX,PYPL,ASO,GME
J&J (JNJ) COVID-19 Vaccine Gets Conditional Approval in Europe
by Zacks Equity Research
J&J's (JNJ) single-shot COVID-19 vaccine set to be available in Europe from April.
Dow Hits New All-Time High Close as Rescue Bill Passes
by Mark Vickery
Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.
VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study
by Zacks Equity Research
VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.
Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains
by Zacks Equity Research
Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.
Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II
by Zacks Equity Research
Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.
Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine
by Zacks Equity Research
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
Pfizer's (PFE) Lorbrena Gets FDA Nod for First-Line Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets approval in the United States.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
FDA Emergency Nod for J&J COVID-19 Vaccine Heats Up Competition
by Kinjel Shah
J&J's (JNJ) single shot COVID-19 vaccine gets FDA emergency use authorization. U.S. CDC Advisory Committee also recommends J&J's vaccine.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Johnson & Johnson
What's in the Cards for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs
by Kinjel Shah
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.
Pfizer (PFE), BioNTech Test COVID-19 Vaccine in Pregnant Women
by Zacks Equity Research
Pfizer (PFE) and BioNTech begin dosing in a mid-to-late-stage study on their COVID-19 vaccine in healthy pregnant women.
4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $118.03 in the latest trading session, marking a -1.11% move from the prior day.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $117.56 in the latest trading session, marking a -0.39% move from the prior day.
Markets Return to Normalcy
by Zacks Equity Research
Markets Return to Normalcy
Groundhog Day, But Nothing's the Same: Q4 for PFE, UPS
by Mark Vickery
We can also take a look at GameStop (GME), AMC Entertainment (AMC) and the silver commodity and recognize that it's not "deja vu all over again" (to quote Yogi Berra); it is a return to valuation normalcy.
Personal Income Increased in December
by Zacks Equity Research
Personal Income Increased in December
Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data
by Mark Vickery
With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.
Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets
by Mark Vickery
The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.